These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cognition enhancers between treating and doping the mind. Lanni C; Lenzken SC; Pascale A; Del Vecchio I; Racchi M; Pistoia F; Govoni S Pharmacol Res; 2008 Mar; 57(3):196-213. PubMed ID: 18353672 [TBL] [Abstract][Full Text] [Related]
4. Just treat, or enhance? Kennedy D Science; 2004 Apr; 304(5667):17. PubMed ID: 15060288 [No Abstract] [Full Text] [Related]
5. Some first steps toward responsible use of cognitive-enhancing drugs by the healthy. Greely HT Am J Bioeth; 2013; 13(7):39-41. PubMed ID: 23767438 [No Abstract] [Full Text] [Related]
6. Enhancing cognition in the intellectually intact. Whitehouse PJ; Juengst E; Mehlman M; Murray TH Hastings Cent Rep; 1997; 27(3):14-22. PubMed ID: 9219019 [TBL] [Abstract][Full Text] [Related]
7. [The consequences of closed traumatic brain injury and piracetam efficacy in their treatment in adolescents]. Zavadenko NN; Guzilova LS Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(3):43-8. PubMed ID: 18427539 [TBL] [Abstract][Full Text] [Related]
8. Memory enhancement: the progress and our fears. Gerlai R Genes Brain Behav; 2003 Aug; 2(4):187-8; discussion 189-90. PubMed ID: 12953784 [TBL] [Abstract][Full Text] [Related]
9. Part II. Cognitive domains for pharmacological intervention: implications for neuropsychiatric and neurological illnesses. Handb Exp Pharmacol; 2015; 228():157-9. PubMed ID: 26317140 [No Abstract] [Full Text] [Related]
10. Sequelae of closed craniocerebral trauma and the efficacy of piracetam in its treatment in adolescents. Zavadenko NN; Guzilova LS Neurosci Behav Physiol; 2009 May; 39(4):323-8. PubMed ID: 19340573 [TBL] [Abstract][Full Text] [Related]
11. Constraints on regulatory options for putatively cognitive enhancing drugs. Hall W; Partridge B; Lucke J Am J Bioeth; 2013; 13(7):35-7. PubMed ID: 23767436 [No Abstract] [Full Text] [Related]
14. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Dunbar G; Boeijinga PH; Demazières A; Cisterni C; Kuchibhatla R; Wesnes K; Luthringer R Psychopharmacology (Berl); 2007 May; 191(4):919-29. PubMed ID: 17225162 [TBL] [Abstract][Full Text] [Related]
15. Navigating the enhancement landscape. Ethical issues in research on cognitive enhancers for healthy individuals. Forlini C; Hall W; Maxwell B; Outram SM; Reiner PB; Repantis D; Schermer M; Racine E EMBO Rep; 2013 Feb; 14(2):123-8. PubMed ID: 23318628 [No Abstract] [Full Text] [Related]
16. [Neuro-enhancement from an addiction specialist's viewpoint]. Soyka M Nervenarzt; 2009 Jul; 80(7):837-9. PubMed ID: 19543877 [TBL] [Abstract][Full Text] [Related]
17. Neurocognitive enhancement: what can we do and what should we do? Farah MJ; Illes J; Cook-Deegan R; Gardner H; Kandel E; King P; Parens E; Sahakian B; Wolpe PR Nat Rev Neurosci; 2004 May; 5(5):421-5. PubMed ID: 15100724 [No Abstract] [Full Text] [Related]
18. Forgetting and remembering. A star-studded search for memory-enhancing drugs. Marshall E Science; 2004 Apr; 304(5667):36-8. PubMed ID: 15060299 [No Abstract] [Full Text] [Related]
19. The neuropharmacology of L-theanine(N-ethyl-L-glutamine): a possible neuroprotective and cognitive enhancing agent. Nathan PJ; Lu K; Gray M; Oliver C J Herb Pharmacother; 2006; 6(2):21-30. PubMed ID: 17182482 [TBL] [Abstract][Full Text] [Related]
20. Ethical issues in the use of cognitive enhancement. Darby R Pharos Alpha Omega Alpha Honor Med Soc; 2010; 73(2):16-22. PubMed ID: 20455376 [No Abstract] [Full Text] [Related] [Next] [New Search]